-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Edited by WuXi AppTec Content Team
GentiBio today announced a collaboration with Bristol-Myers Squibb (BMS) to co-develop novel engineered regulatory T cells (Treg) to help rebuild immune tolerance and repair tissue in patients with inflammatory bowel disease (IBD)Inflammatory bowel disease is a debilitating and life-threatening chronic inflammation of the gastrointestinal tract
[1] GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases.
[2] BMS Bets up to $1.
Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress